NR2B subunit blockade does not affect motor symptoms induced by 3-nitropropionic acid
Broad-spectrum N-methyl D-aspartate (NMDA) antagonists, although proposed in therapies for several pathologies including Huntington's disease (HD), can produce dramatic side-effects. Thus, the therapeutic potential of subunit selective NMDA receptor antagonists warrants investigation. Overactivation of NMDA receptors containing the NR2B subunit plays a pathogenic role in HD, suggesting a neuroprotective potential of selective NR2B blockade. In the present study, we investigated whether the selective NR2B receptor antagonist, R-(R*,S*)-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidinepropanol, could also affect motor symptoms in mice intoxicated with 3-nitropropionic acid (3-NP), a phenotypic model of HD. NR2B subunit acute blockade had no effect on spontaneous activity, HD-like symptoms (clinical scale), and sensorimotor performances (beam task) in 3-NP intoxicated mice. These results suggest that selective NR2B antagonism has no acute symptomatic effect on motor and sensorimotor impairments due to 3-NP-induced striatal injury.
Keywords: 3-nitropropionic acid ; Motor behavior ; Nmda ; NR2B subunit ; NR2B antagonist ; Ro 25-6981 ; Huntingtons-Disease ; Striatonigral Degeneration ; Mice ; Model ; Excitotoxicity ; Antagonists ; Riluzole ; Deficits
Record created on 2011-12-16, modified on 2016-08-09